Tarsus Pharmaceuticals announced its management will participate in the William Blair 46th Annual Growth Stock Conference on June 2 and the 2026 Jefferies Global Healthcare Conference on June 3. These events provide Tarsus an opportunity to showcase its advancements in eye care treatments, including its FDA-approved drug XDEMVY® for Demodex blepharitis and its pipeline candidates for ocular rosacea and Lyme disease prevention. Investors can access live webcasts and replays on the company's website. This participation highlights Tarsus's ongoing efforts to engage with investors and promote its innovative pharmaceutical developments.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
